Q-omics provides the consensus-scored CHRNA4 profile across patient tissues and cancer cell-line models. CHRNA4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CHRNA4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CHRNA4 RNA expression shows 12,683 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, KIRC, and TGCT as cancer lineages where CHRNA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHRNA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHRNA4 survival associations across molecular data types. CHRNA4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHRNA4 RNA expression–survival associations across cancer types. High CHRNA4 expression shows unfavorable associations in KICH, ACC, STAD and LUAD, but favorable associations in LGG and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CHRNA4 RNA expression.
This table summarizes CHRNA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CHRNA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHRNA4 shows lower tumor expression in KIRC, KIRP, THCA, COAD, KICH and LIHC. The KIRC box plot shows higher CHRNA4 RNA expression in normal versus tumor tissue (log2 FC = −0.826, t-test p < 0.001).
This table shows molecular features associated with CHRNA4 in patient tissues and cancer cell lines. In patient samples, CHRNA4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CHRNA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
